Net Cash Provided by (Used in) Financing Activities of Intra-Cellular Therapies, Inc. from 30 Jun 2013 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Intra-Cellular Therapies, Inc. annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 30 Jun 2013 to 31 Dec 2024.
  • Intra-Cellular Therapies, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2024 was $9,989,000, a 174% increase year-over-year.
  • Intra-Cellular Therapies, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $567,508,000, a 3086% increase from 2023.
  • Intra-Cellular Therapies, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $17,810,000, a 96% decline from 2022.
  • Intra-Cellular Therapies, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $455,159,000, a 3851% increase from 2021.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

Intra-Cellular Therapies, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $567,508,000 +$549,698,000 +3086% 01 Jan 2024 31 Dec 2024 10-K 21 Feb 2025 2024 FY
2023 $17,810,000 -$437,349,000 -96% 01 Jan 2023 31 Dec 2023 10-K 21 Feb 2025 2024 FY
2022 $455,159,000 +$443,640,000 +3851% 01 Jan 2022 31 Dec 2022 10-K 21 Feb 2025 2024 FY
2021 $11,519,000 -$652,658,000 -98% 01 Jan 2021 31 Dec 2021 10-K 22 Feb 2024 2023 FY
2020 $664,177,000 +$660,941,399 +20427% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
2019 $3,235,601 +$2,550,413 +372% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $685,188 -$161,672,228 -100% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $162,357,416 +$161,879,682 +33885% 01 Jan 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
2016 $477,734 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY

Intra-Cellular Therapies, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $9,989,000 +$6,349,000 +174% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q1 2023 $3,640,000 -$438,174,000 -99% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q1 2022 $441,814,000 +$440,382,000 +30753% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q1 2021 $1,432,000 -$276,135,347 -99% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q1 2020 $277,567,347 +$277,536,111 +888514% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q1 2019 $31,236 -$306,560 -91% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q1 2018 $337,796 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q2 2013 $5,900* 01 Apr 2013 30 Jun 2013 10-Q 15 Aug 2013 2013 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.